Stock Ratings / Health Care / CRSP / earnings

SRRK (42) CGON (42) IMVT (37) ADPT (51) ⌘ Pro Terminal →

CRISPR Therapeutics AG (CRSP) Next Earnings Date & Expected ±10.5% Move

$54.26 +0.28% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

CRISPR Therapeutics AG (CRSP) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $5.25B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D

Each axis scored 0–20

12M PRICE TARGET CONE-6.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CRSP)Realized 20D OHLCV Swing Band: ±10.5%

NEXT EST. WINDOW: Dec 30, 2026 (~58 DAYS)

Historical OHLCV Volatility ±10.5% Swing Band

±$5.70 Expected Swing

MODEL EARNINGS SETUP GAUGE

CRSP Quantitative Pre-Earnings Setup: 44/100

Trailing EPS: $-6.01 • YoY Revenue Growth: -65%

Model Bullish Setup (44/100)Model Risk Weight (56/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-12-31	$3.5M	-$581.6M	-$345.9M	52%
FY 2024	2024-12-31	$37.3M	-$366.3M	-$144.7M	52%
FY 2023	2023-12-31	$371.2M	-$153.6M	-$277.1M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CRSP)

✓Walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

CRSP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.27%▼ DESCENDING CHANNEL

2026-11-01O $54.11H $54.26L $54.11C $54.26VOL 1.31M

RES: $59.55SUP: $46.45SMA50: $54.08SMA200: $52.88

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CRSP Butterfly Map → + Track CRSP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

21.4%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for CRSP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CRSP)

Health Care Rank #167 of 188 ⚔️ SRRK vs CRSP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CRSP vs. SRRK, CGON, IMVT, ADPT)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (26 Tracked Issuers)

Across 188 tracked Health Care securities in the Roarable RQD universe, CRISPR Therapeutics AG (CRSP) ranks #167 by composite RQD confidence (44/100, grade D) and #159 by equity capitalization ($5.25B). Within this direct 5-issuer industry benchmark cohort, CRSP leads on earnings valuation at N/A trailing P/E, while ADPT leads on capital efficiency and profitability with -12.5% ROIC and 74.2% gross margin. ADPT currently holds the highest overall quantitative score in the immediate peer group at 51/100 (D) compared with CRSP at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
CRSP ACTIVE CRISPR Therapeutics AG	D	44/100	—	—	-30.6%	+0.28%	$5.25B	Benchmark Subject
SRRK Scholar Rock Holding Corporation	D-	42/100	—	—	-35.0%	+2.15%	$5.38B	/srrk-vs-crsp →
CGON CG Oncology Inc.	D-	42/100	—	—	-20.8%	-0.77%	$5.63B	/cgon-vs-crsp →
IMVT Immunovant Inc.	D-	37/100	—	—	-35.0%	+0.75%	$6.12B	/imvt-vs-crsp →
ADPT Adaptive Biotechnologies Corporation	D	51/100	—	74.2%	-12.5%	-0.70%	$4.50B	/adpt-vs-crsp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001674416

In its most recent audited fiscal period (FY2025, filed 2025-12-31), CRISPR Therapeutics AG (CRSP) reported GAAP revenue of $3.5M (-90.6% vs. FY2024 revenue of $37.3M , and -99.1% cumulative change since FY2023) , GAAP net income of -$581.6M, operating cash flow of -$345.0M, and free cash flow of -$345.9M (-139.1% YoY). On the balance sheet, CRSP closed FY2025 with $2.27B in total assets against $154.5M in total debt (Altman Z-Score: 7.97, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$3.5M	-$581.6M	-$345.0M	-$345.9M	$2.27B	$154.5M
FY2024 (FY)	2024-12-31	$37.3M	-$366.3M	-$142.8M	-$144.7M	$2.24B	$139.5M
FY2023 (FY)	2023-12-31	$371.2M	-$153.6M	-$260.4M	-$277.1M	$2.89B	$675.2M

3. CRSP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CRSP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, CRISPR Therapeutics AG (NASDAQ: CRSP) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $54.26 (+0.28% 1D, market cap $5.25B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 9/20, and SEC Balance-Sheet Forensics 5/20. Across 188 tracked Health Care issuers, CRSP ranks #167 in composite RQD confidence.

How does CRSP compare to SRRK and CGON in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), CRSP carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -30.6%. By comparison, SRRK (Scholar Rock Holding Corporation) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $5.38B) and CGON (CG Oncology Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -20.8%, cap $5.63B). Among the 5-stock peer group, CRSP leads on earnings multiple (N/A) while ADPT leads on capital efficiency (-12.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CRSP?

Per CRSP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001674416), CRISPR Therapeutics AG generated $3.5M in revenue (-90.6% YoY), -$581.6M in net income, and -$345.9M in free cash flow against $2.27B in total assets and $154.5M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CRSP trading relative to its 50-day, 200-day, and 52-week technical levels?

CRSP last traded at $54.26 (+0.28% on volume of 1,314,288 shares), positioning the stock +0.33% above its 50-day simple moving average ($54.08) and +2.61% above its 200-day simple moving average ($52.88). Across its 52-week range of $44.12 to $65.98, CRSP sits at the 46.4% percentile with a 14-day RSI of 54.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.5% ($48.56 to $59.96).

CRSP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is CRSP's next earnings date?

Based on SEC filing cadence, CRISPR Therapeutics AG (CRSP)'s next quarterly reporting window is estimated around Dec 30, 2026.

How much is CRSP stock expected to move on earnings?

Volatility modeling currently projects a ±10.5% event move for CRSP, spanning a range between $48.56 and $59.96.

Direct Sub-Reports: CRSP RQD Cockpit CRSP 12M Forecast CRSP Earnings & Move CRSP Dividends & DRIP CRSP Insiders & 13F CRSP Whale Options CRSP Profit Sankey CRSP News & Why